X4 Pharmaceuticals Inc. (XFOR)
XFOR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$2.60
-7.80% on the day
Market cap
$257.8M
Micro cap
Revenue · 2025
$6.5M
+150.0% on 2024
Net income · 2025
-$79.2M
-1218.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | XFOR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001501697 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $6.5M |
| Net income | -$79.2M |
| Operating income | -$86.9M |
| Net margin | -1218.4% |
| Operating margin | -1336.7% |
| Revenue growth | +150.0% |
| Cash | $217.0M |
| Total assets | $290.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 39.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-05-06 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-10-08 |
| Latest proxy | DEFA14A | 2026-03-20 |
Source: SEC EDGAR submissions feed, 815 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PALI | Palisade Bio Inc. | $1.47 | -7.86% | $255.3M |
| IPSC | Century Therapeutics Inc. | $1.38 | -4.17% | $249.9M |
| IKT | Inhibikase Therapeutics Inc. | $1.76 | -4.61% | $245.6M |
| SABS | SAB Biotherapeutics Inc. | $2.68 | -5.30% | $243.8M |
| SRZN | Surrozen Inc. | $23.51 | -5.05% | $276.3M |
| FATE | Fate Therapeutics Inc. | $2.00 | -6.10% | $239.6M |
| CABA | Cabaletta Bio Inc. | $1.69 | -5.59% | $286.5M |
| LCTX | Lineage Cell Therapeutics Inc. | $0.9083 | -4.80% | $229.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier